<VariationArchive VariationID="930113" VariationName="NM_001429.4(EP300):c.3014_3015del (p.Asp1004_Cys1005insTer)" VariationType="Deletion" Accession="VCV000930113" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2020-07-04" MostRecentSubmission="2020-07-04">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="918471" VariationID="930113">
      <GeneList>
        <Gene Symbol="EP300" FullName="E1A binding protein p300" GeneID="2033" HGNC_ID="HGNC:3373" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>22q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41092592" stop="41180077" display_start="41092592" display_stop="41180077" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41488613" stop="41576080" display_start="41488613" display_stop="41576080" Strand="+" />
          </Location>
          <OMIM>602700</OMIM>
          <Haploinsufficiency last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">No evidence available</Triplosensitivity>
        </Gene>
        <Gene Symbol="LOC126863158" FullName="BRD4-independent group 4 enhancer GRCh37_chr22:41547383-41548582" GeneID="126863158" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>22q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41151379" stop="41152578" display_start="41151379" display_stop="41152578" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_001429.4(EP300):c.3014_3015del (p.Asp1004_Cys1005insTer)</Name>
      <CanonicalSPDI>NC_000022.11:41152220:TGT:T</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41152221" stop="41152222" display_start="41152221" display_stop="41152222" variantLength="2" positionVCF="41152220" referenceAlleleVCF="CTG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41548225" stop="41548226" display_start="41548225" display_stop="41548226" variantLength="2" positionVCF="41548224" referenceAlleleVCF="CTG" alternateAlleleVCF="C" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.41548226_41548227del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.41548226_41548227del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.41152222_41152223del" Assembly="GRCh38">
            <Expression>NC_000022.11:g.41152222_41152223del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009817.1" sequenceAccession="NG_009817" sequenceVersion="1" change="g.64613_64614del">
            <Expression>NG_009817.1:g.64613_64614del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001362843.2" sequenceAccession="NM_001362843" sequenceVersion="2" change="c.2936_2937del">
            <Expression>NM_001362843.2:c.2936_2937del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001349772.1" sequenceAccession="NP_001349772" sequenceVersion="1" change="p.Asp978_Cys979insTer">
            <Expression>NP_001349772.1:p.Asp978_Cys979insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001429.4" sequenceAccession="NM_001429" sequenceVersion="4" change="c.3014_3015del" MANESelect="true">
            <Expression>NM_001429.4:c.3014_3015del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001420.2" sequenceAccession="NP_001420" sequenceVersion="2" change="p.Asp1004_Cys1005insTer">
            <Expression>NP_001420.2:p.Asp1004_Cys1005insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422" sequenceAccession="LRG_1422">
            <Expression>LRG_1422:g.64613_64614del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422t1" sequenceAccession="LRG_1422t1">
            <Expression>LRG_1422t1:c.3014_3015del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1422p1" sequenceAccession="LRG_1422p1" change="p.Asp1004_Cys1005insTer">
            <Expression>LRG_1422p1:p.Asp1004_Cys1005insTer</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2059050320" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001429.4(EP300):c.3014_3015del (p.Asp1004_Cys1005insTer) AND Rubinstein-Taybi syndrome" Accession="RCV001195547" Version="5">
        <ClassifiedConditionList TraitSetID="46378">
          <ClassifiedCondition DB="MedGen" ID="C0035934">Rubinstein-Taybi syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-04-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-04-04" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-07-04" MostRecentSubmission="2020-07-04">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="46378" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="41364" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome</ElementValue>
                <XRef ID="Rubinstein-Taybi+syndrome/6372" DB="Genetic Alliance" />
                <XRef ID="MONDO:0019188" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS180849" DB="OMIM" />
                <XRef ID="45582004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Broad thumb-hallux syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">RSTS</ElementValue>
                <XRef Type="MIM" ID="180849" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RSTS1</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7593" />
                <XRef ID="7593" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C0035934" DB="MedGen" />
              <XRef ID="MONDO:0019188" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS180849" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2693829" SubmissionDate="2020-05-14" DateLastUpdated="2020-07-04" DateCreated="2020-07-04">
        <ClinVarSubmissionID localKey="96196159|Orphanet:ORPHA783" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001365932" DateUpdated="2020-07-04" DateCreated="2020-07-04" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-04-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The p.Cys1005X variant in EP300 has not been previously reported in individuals with Rubenstein-Taybi syndrome 2 and is absent from large population studies. However, this variant was confirmed to be de novo in an individual with moderate intellectual disability, autism, corpus callosum hypoplasia, ventriculomegaly, low columella, and dental crowding by the Broad Institute Rare Genomes Project. This variant is predicted to cause a frameshift, which alters the proteinâ€™s amino acid sequence beginning at position 1005 and leads to a premature termination codon at this position. This alteration is then predicted to lead to absent protein. Heterozygous loss of function of the EP300 gene is an established disease mechanism in individuals with Rubenstein-Taybi syndrome 2. In summary, this variant meets criteria to be classified as pathogenic for Rubenstein-Taybi syndrome 2 in an autosomal dominant manner based upon de novo occurrence, its absence from the general population, and its predicted impact on the protein. ACMG/AMP Criteria applied: PVS1, PS2, PM2.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LMM Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">24033266</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EP300" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.41548226_41548227delGT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA783" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7448406</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2693829" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA783" MappingRef="Orphanet">
        <MedGen CUI="C0035934" Name="Rubinstein-Taybi syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

